[March 09, 2016]

Deciphera Pharmaceuticals to Present at American Chemical Society Annual Meeting

Deciphera Pharmaceuticals, a clinical-stage biotechnology company focused on developing advanced kinase inhibitor treatments targeting the tumor cell and the tumor microenvironment, today announced that Daniel Flynn, Ph.D., Deciphera's Chief Scientific Officer and Founder will give a plenary talk at the upcoming 251st National Meeting & Exposition of the American Chemical Society (ACS (News - Alert)), taking place March 13-17, 2016 in San Diego.

Dr. Flynn's oral presentation (abstract#: MEDI 240), titled "Mining kinase type II inactive conformations: Switch control inhibition as an advanced platform for increasing inhibitor durability and selectivity," will be presented at 4:00 p.m. PT on Tuesday, March 15, 2016 during the Division of Medicinal Chemistry session on Advances in Development of Type II Kinase Inhibitors, in room 6E of the San Diego Convenion Center.

"I am looking forward to discussing the differentiating attributes of switch control inhibition at the upcoming ACS meeting," said Dr. Flynn. "Using examples from the Deciphera pipeline I will demonstrate the ability of switch control inhibitors to durably inhibit target kinases and virtually all of their mutant forms, maintain resiliency at high ATP (News - Alert) concentrations and be designed for highly-specific or spectrum-selective inhibition as needed."

About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals seeks to improve treatment for patients with cancer by designing kinase inhibitor therapies that target the hallmarks of cancer biology. We specifically design our small molecule compounds to simultaneously block multiple cancer signaling mechanisms in the tumor cell and the tumor microenvironment to prevent growth and spread. Deciphera's unique approach represents an important advance over current therapies in the durability of kinase inhibition and resiliency to genetic mutations to provide greater benefit across a range of cancers. Deciphera's business strategy is to advance its drug candidates for genetically defined cancers and cancers that target the tumor microenvironment through both proprietary and partnered programs.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160309005245/en/

[ Back To TMCnet.com's Homepage ]